EGFR and non-small cell lung carcinoma: In support of the clinical value of liquid biopsy in advanced stages is the finding that the response rates of patients with NSCLC positive for EGFR–T790M in plasma exhibited outcomes equivalent to patients who were classified by a tissue-based assay [17,18].